Why dabigatran is worth to be chosen? The cardiologist’s point of view based on the recent data available Review article
Article Sidebar
Main Article Content
Abstract
The introduction of oral anticoagulants that are not vitamin K antagonists (NOAC, non-vitamin K antagonist oral anticoagulants) has become a breakthrough in anticoagulant therapy. These drugs offer a constant level of anticoagulation, no need for periodic monitoring of coagulation parameters, and adjusting the daily dose of the drug, which ensures comfort and effectiveness of the therapy. A special place among NOAC has dabigatran as an attractive form of treatment in both acute thrombosis and the prevention of thromboembolic events in patients at increased risk. The efficacy and safety of dabigatran in various clinical situations has been confirmed by the results of many clinical trials as well as nearly 7 years of experience from everyday practice. The most numerous group of patients benefiting from the use of dabigatran are those with AF and at least 1 stroke risk factor, who may continue their treatment in the same way, also in case of electrical cardioversion, ablation or stenting of coronary vessels. A special advantage of dabigatran is the fact that as the only one of NOAC has a specific antidote that quickly and effectively reverses its action, which is particularly important in life-threatening bleeds or the need for surgical intervention, significantly increasing the safety and comfort of treatment with this preparation.
Article Details
Copyright © by Medical Education. All rights reserved.
References
2. White H.D., Gruber M., Feyzi J. et al.: Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch. Intern. Med. 2007; 167(3): 239-245.
3. Eriksson B.I., Dahl O.E., Rosencher N. et al.: Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J. Thromb. Haemost. 2007; 5: 2178-2185.
4. Connolly S.J., Ezekowitz M.D., Yusuf S. et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361(12): 1139-1151.
5. Camm A.J., Lip G.Y., De Caterina R. et al.: 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur. Heart J. 2012; 33: 2719-2747.
6. Connolly S.J., Wallentin L., Ezekowitz M.D. et al.: The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 2013; 16(128): 237-243.
7. Larsen T.B., Rasmussen L.H., Skjoth F. et al.: Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: A prospective nationwide cohort study. J. Am. Coll. Cardiol. 2013; 61: 2264-2273.
8. Pollack C.V. Jr, Reilly P.A., Eikelboom J. et al.: Idarucizumab for Dabigatran Reversal. N. Engl. J. Med. 2015; 373(6): 511-520.
9. Calkins H., Willems S., Gerstenfeld E.P. et al.: Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N. Engl. J. Med. 2017; 376(17): 1627-1636.
10. Cannon C.P., Bhatt D.L., Oldgren J. et al.: RE-DUAL PCI Steering Committee and Investigators. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N. Engl. J. Med. 2017; 377(16): 1513-1524.
11. Charakterystyka Produktu Leczniczego Pradaxa.
12. Charakterystyka Produktu Leczniczego Praxbind.
13. Nagarakanti R., Ezekowitz M.D., Oldgren J.: Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131-136.